echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Endocrine System > Diabetes Care: Enpagliflozin may become the first drug to reverse brain insulin resistance and improve body fat and metabolism!

    Diabetes Care: Enpagliflozin may become the first drug to reverse brain insulin resistance and improve body fat and metabolism!

    • Last Update: 2021-11-12
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Englitazone net SGLT2 inhibitors belong to a new generation, in August 2014 by the US Food and Drug Administration Bureau ( the FDA ) approved after September 2017 approved the listing in mainland China


    Manage FDA diabetes

    Unlike other oral drugs currently used to treat type II diabetes, Enge's first column is the net SGLT2 class of antidiabetic agents complete heart blood vessels prognosis, it is the only one oral hypoglycemic agents were studied confirmed sugar control, The four-fold curative effect of protecting the heart, protecting the kidney and reducing weight


    Engel is the first column net SGLT2 class of antidiabetic drugs only complete cardiac vascular prognosis, it is the only one oral hypoglycemic agents have been shown to control sugar research, protect the heart, kidneys, and quadruple the effect of weight loss


    Because SGLT2 inhibitors can lower glucose levels and regulate energy metabolism, some researchers have hypothesized that SGLT2 inhibitors may be a pharmacological method to reverse insulin resistance in the brain and have carried out corresponding studies.


    In this randomized, double-blind, placebo-controlled clinical trial, 40 prediabetes patients (60±9 years old; BMI 31.


    It turns out that there is a significant interaction between time and treatment in the response of the hypothalamus to insulin


    Post-mortem analysis showed that only patients treated with empagliflozin had an increase in hypothalamic insulin responsiveness


    The effect of Enpagliflozin on systemic insulin sensitivity (M value under high insulin conditions [40 IU/m2 body surface area/min]

    This result confirms insulin resistance in the hypothalamus of human prediabetic patients


    Treatment with empagliflozin for 8 weeks can restore hypothalamic insulin sensitivity, which is a favorable response and may contribute to the beneficial effects of SGLT2 inhibitors


    In summary, SGLT2 inhibitors are the first drugs to reverse brain insulin resistance and have potential benefits for fat and systemic metabolism


     

    references:

    Empagliflozin Improves Insulin Sensitivity of the Hypothalamus in Humans With Prediabetes: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial.


    Empagliflozin Improves Insulin Sensitivity of the Hypothalamus in Humans With Prediabetes: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial.


    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.